Pathogenesis of Hypertension

Annals of Internal Medicine

Volumn 139, Issue 9, 2003, Pages 761-776

  Oparil, Suzanne ^a,b   Zaman, M Amin ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; THIAZIDE DIURETIC AGENT; URIC ACID;

AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; HYPERTENSION; HYPERURICEMIA; INHERITANCE; LIVER TOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIDE EFFECT; SYMPATHETIC TONE; TERATOGENICITY; TESTIS ATROPHY; TREATMENT OUTCOME; GENETICS; RISK FACTOR;

HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0642341369     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-9-200311040-00011     Document Type: Review

References (118)

1. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101:329-35. [PMID: 10645931]
2. Calhoun DA, Bakir SE, Oparil S. Etiology and pathogenesis of essential hypertension. In: Crawford MH, DiMarco JP, eds. Cardiology. London: Mosby International; 2000:3.1-3.10.
3. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-56. [PMID: 11239411]
4. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913-23. [PMID: 11907292]
5. Guyton AC. Blood pressure control - special role of the kidneys and body fluids. Science. 1991;252:1813-6. [PMID: 2063193]
6. Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol. 1977;106:284-5. [PMID: 562066]
7. Longini IM Jr, Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol. 1984;120:131-44. [PMID: 6741914]
8. Biron P, Mongeau JG, Bertrand D. Familial aggregation of blood pressure in 558 adopted children. Can Med Assoc J. 1976;115:773-4. [PMID: 974967]
9. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293:1107-12. [PMID: 11498583]
10. Hsueh WC, Mitchell BD, Schneider JL, Wagner MJ, Bell CJ, Nanthakumar E, et al. QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish. Circulation. 2000;101:2810-6. [PMID: 10859286]
11. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension. 2000;36:477-83, [PMID: 11040222]
12. Kristjansson K, Manolescu A, Kristinsson A, Hardarson T, Knudsen H, Ingason S, et al. Linkage of essential hypertension to chromosome 18q. Hypertension. 2002;39:1044-9. [PMID: 12052839]
13. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF. Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension. 2002;40:1-6. [PMID: 12105129]
14. Harrap SB. Genetics. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: WB Saunders; 2000:29-42.
15. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-80. [PMID: 1394429]
16. Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X. Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Hypertension. 1999;33:1324-31. [PMID: 10373210]
17. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens. 1999;17:9-17. [PMID: 10100088]
18. Fornage M, Amos CI, Kardia S, Sing CF, Turner ST, Boerwinkle E. Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation. 1998;97:1773-9. [PMID: 9603530]
19. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation. 1998;97:1766-72. [PMID: 9603529]
20. Niu T, Yang J, Wang B, Chen W, Wang Z, Laird N, et al. Angiotensinogen gene polymorphisms M235T/T174M: no excess transmission to hypertensive Chinese. Hypertension. 1999;33:698-702. [PMID: 10024331]
21. Luft FC. Molecular genetics of human hypertension. Curr Opin Nephrol Hypertens. 2000;9:259-66. [PMID: 10847327]
22. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407-14. [PMID: 7954808]
23. Melander O, Orho M, Fagerudd J, Bengtsson K, Groop PH, Mattiasson I, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension. 1998;31:1118-24. [PMID: 9576123]
24. Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001;281:C1413-21. [PMID: 11600403]
25. Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR. Concordance for dyslipidemic hypertension in male twins. JAMA. 1991;265:2079-84. [PMID: 2013927]
26. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. [PMID: 9673301]
27. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-81. [PMID: 8538710]
28. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl. 1996;14:S159-65. [PMID: 9120673]
29. Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens. 2000;13:112S-122S. [PMID: 10921530]
30. Kim JR, Kiefe CI, Liu K, Williams OD, Jacobs DR Jr, Oberman A. Heart rate and subsequent blood pressure in young adults: the CARDIA study. Hypertension. 1999;33:640-6. [PMID: 10024320]
31. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13:99S-105S. [PMID: 10921528]
32. Chapleau MW, Hajduczok G, Abboud FM. Mechanisms of resetting of arterial baroreceptors: an overview. Am J Med Sci. 1988;295:327-34. [PMID: 2834951]
33. Guo GB, Thames MD, Abboud FM. Arterial baroreflexes in renal hypertensive rabbits. Selectivity and redundancy of baroreceptor influence on heart rate, vascular resistance, and lumbar sympathetic nerve activity. Circ Res. 1983;53:223-34. [PMID: 6883646]
34. Xie PL, Chapleau MW, McDowell TS, Hajduczok G, Abboud FM. Mechanism of decreased baroreceptor activity in chronic hypertensive rabbits. Role of endogenous prostanoids. J Clin Invest. 1990;86:625-30. [PMID: 2117025]
35. Xie PL, McDowell TS, Chapleau MW, Hajduczok G, Abboud FM. Rapid baroreceptor resetting in chronic hypertension. Implications for normalization of arterial pressure. Hypertension. 1991;17:72-9. [PMID: 1986984]
36. Guo GB, Abboud FM. Impaired central mediation of the arterial baroreflex in chronic renal hypertension. Am J Physiol. 1984;246:H720-7. [PMID: 6720985]
37. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol. 1984;246:H80-9. [PMID: 6696093]
38. Abboud FM. Effects of sodium, angiotensin, and steroids on vascular reactivity in man. Fed Proc. 1974;33:143-9. [PMID: 4359754]
39. Li Z, Mao HZ, Abboud FM, Chapleau MW. Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res. 1996;79:802-11. [PMID: 8831504]
40. Chapleau MW, Hajduczok G, Abboud FM. Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. Am J Physiol. 1992;263:R103-8. [PMID: 1636777]
41. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension. 1988;11:608-12. [PMID: 3391673]
42. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897-904. [PMID: 7560081]
43. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation. 1994;90:928-36. [PMID: 8044964]
44. Grassi G, Giannattasio C, Failla M, Pesenti A, Peretti G, Marinoni E, et al. Sympathetic modulation of radial artery compliance in congestive heart failure. Hypertension. 1995;26:348-54. [PMID: 7635545]
45. Esler M, Jennings G, Lambert G, Meredith I, Home M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963-85. [PMID: 1977182]
46. Hollenberg NK, Adams DF, Solomon H, Chenitz WR, Burger BM, Abrams HL, et al. Renal vascular tone in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators. Medicine (Baltimore). 1975;54:29-44. [PMID: 235062]
47. DiBona GF, Kopp UC. Neural control of renal function: role in human hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Edition. Laragh JH, Brenner BM, eds. New York: Raven Pr; 1995:1349-58.
48. Thorén P, Ricksten SE. Recordings of renal and splanchnic sympathetic nervous activity in normotensive and spontaneously hypertensive rats. Clin Sci (Lond). 1979;57 Suppl 5:197s-199s. [PMID: 540430]
49. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-8. [PMID: 1454086]
50. Ziegler MG, Mills P, Dimsdale JE. Hypertensives' pressor response to norepinephrine. Analysis by infusion rate and plasma levels. Am J Hypertens. 1991;4:586-91. [PMID: 1873013]
51. Bianchetri MG, Bererta-Piccoli C, Weidmann P, Ferrier C. Blood pressure control in normotensive members of hypertensive families. Kidney Int. 1986;29:882-8. [PMID: 3520094]
52. Frohlich ED. Other adrenergic inhibitors and the direct-acting smooth muscle vasodilators. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: WB Saunders; 2000:637-43.
53. Light KC. Environmental and psychosocial stress in hypertension onset and progression. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: WB Saunders; 2000:59-70.
54. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 1993;22:801-5. [PMID: 8244512]
55. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504. [PMID: 6461865]
56. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;70:921-61. [PMID: 2217559]
57. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schifffin EL, et al. Vascular remodeling [Letter]. Hypertension. 1996;28:505-6. [PMID: 8794840]
58. Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens. 2001;10:617-24. [PMID: 11496055]
59. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25:474-81. [PMID: 7721386]
60. Henke F, Lubarsch O, eds. Handbuch der speziellen pathologischen Anatomie und Histologie, Volume VI. Harnorgane männliche Geschlechtsorgane. Berlin, Germany: Julius Springer; 1925;3:368-405.
61. Goldblatt H. The renal origin of hypertension. Physiol Rev. 1947;27:120-65.
62. Julius S. The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens. 1996;18:305-21. [PMID: 8743023]
63. Cowley AW Jr, Mattson DL, Lu S, Roman RJ. The renal medulla and hypertension. Hypertension. 1995;25:663-73. [PMID: 7721413]
64. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142-6. [PMID: 10904027]
65. Welch WJ, Tojo A, Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol. 2000;278:F769-76. [PMID: 10807588]
66. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens. 1988;6:763-77. [PMID: 3058795]
67. Sanai T, Kimura G. Renal function reserve and sodium sensitivity in essential hypertension. J Lab Clin Med. 1996;128:89-97. [PMID: 8759940]
68. Rich MW. Uric acid: is it a risk factor for cardiovascular disease? [Editorial]. Am J Cardiol. 2000;85:1018-21. [PMID: 10760347]
69. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-50. [PMID: 10406838]
70. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13. [PMID: 10391820]
71. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404-10. [PMID: 10815083]
72. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817-21. [PMID: 7447188]
73. Saito I, Satura T, Kondo K, Nakamura R, Oguro T, Yamagami K, et al. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc. 1978;26:241-7. [PMID: 659766]
74. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000;18:1149-54. [PMID: 10954008]
75. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-6. [PMID: 11711505]
76. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-7. [PMID: 11997315]
77. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604-8. [PMID: 2022672]
78. O'Rourke MF, Hayward CS, Lehmann ED. Arterial stiffness. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: WB Saunders; 2000:134-51.
79. Safar ME. Hypothesis on isolated systolic hypertension in the elderly. J Hum Hypertens. 1999;13:813-5. [PMID: 10618669]
80. Heistad DD, Abbound FM, Eckstein JW. Vasoconstrictor response to simulated diving in man. J Appl Physiol. 1968;25:542-9. [PMID: 5687360]
81. Abboud FM, Eckstein JW. Comparative changes in segmental vascular resistance in response to nerve stimulation and to norepinephrine. Circ Res. 1966;18:263-77. [PMID: 5904317]
82. O'Rourke MF, Avolio AP, Lee L. Reduction of wave reflection is the principal beneficial action of felodipine in isolated systolic hypertension [Abstract]. Am J Hypertens. 1997;10:3A-4A.
83. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-72. [PMID: 10752701]
84. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-8. [PMID: 12243636]
85. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999;39:547-59. [PMID: 10354958]
86. Mulvany MJ. Small artery remodeling in hypertension. Curr Hypertens Rep. 2002;4:49-55. [PMID: 11790292]
87. Tea BS, Der Sarkissian S, Touyz RM, Hamet P, deBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension. 2000;35:1069-73. [PMID: 10818066]
88. Carey RM, Siragy HM. Newly recognized components of the Renin-Angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-71. [PMID: 12788798]
89. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997;80:45-51. [PMID: 8978321]
90. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-23. [PMID: 8621776]
91. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassègue B, Griendling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal. 1999;1:167-79. [PMID: 11228745]
92. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998;83:952-9. [PMID: 9797345]
93. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100:1223-9. [PMID: 10484544]
94. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539]
95. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92. [PMID: 12584366]
96. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. [PMID: 11937178]
97. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. [PMID: 11565518]
98. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60. [PMID: 11565517]
99. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Amer P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8. [PMID: 11565519]
100. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72. [PMID: 12748199]
101. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39:S1-246. [PMID: 11904577]
102. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53. [PMID: 12777938]
103. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10. [PMID: 11937179]
104. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. [PMID: 12479763]
105. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-79. [PMID: 10888242]
106. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. [PMID: 10471456]
107. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. [PMID: 12668699]
108. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4:221-8. [PMID: 12003705]
109. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-6. [PMID: 12468575]
110. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-4. [PMID: 11073878]
111. Panza JA. High-normal blood pressure - more "high" than "normal" [Editorial]. N Engl J Med. 2001;345:1337-40. [PMID: 11794154]
112. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Nad Acad Sci U S A. 1991;88:10045-8. [PMID: 1658794]
113. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-93. [PMID: 9024144]
114. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652-5. [PMID: 8843893]
115. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338:784-90. [PMID: 9504938]
116. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-23. [PMID: 11597664]
117. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-86. [PMID: 11519501]
118. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens (Greenwich). 2000;2:324-330. [PMID: 11416669]